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Objective: Early enteral nutrition is beneﬁcial for acute pancreatitis (AP), but the optimal timing and
criteria remain unclear. The aim of this study was to explore the feasibility and safety of early oral
refeeding (EORF) based on hunger in patients with moderate or severe AP.
Methods: In a prospective, single-center, controlled, randomized clinical trial (ChiCTR-TRC-
12002994), eligible patients with moderate or severe AP were randomized to either EORF or
conventional oral refeeding (CORF). Patients in the EORF group restarted an oral diet when they felt
hungry, regardless of laboratory parameters. Those in the CORF group restarted an oral diet only
when clinical and laboratory symptoms had resolved. Clinical outcomes were compared between
the two groups.
Results: In all, 146 eligible patients with moderate or severe AP were included and randomized to the
EORF (n ¼ 70) or CORF (n ¼ 76) group. There were eight dropouts after randomization (three in EORF
group; ﬁve in CORF group). The groups had similar baseline characteristics. The total length of hos-
pitalization (13.7  5.4 d versus 15.7  6.2 d; P ¼ 0.0398) and duration of fasting (8.3  3.9 d versus
10.5  5.1 d; P ¼ 0.0047) were shorter in the EORF group than in the CORF group. There was no
difference in the number of adverse events or complications between the two groups. Themean blood
glucose level after oral refeeding was higher in the EORF group than in the CORF group (P ¼ 0.0030).
Conclusions: This controlled, randomized clinical trial conﬁrmed the effectiveness and feasibility of
EORF based on hunger in patients with moderate or severe AP. EORF could shorten the length of
hospitalization in patients with moderate or severe AP.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Acute pancreatitis (AP) is a leading cause of hospitalization
worldwide, and nutritional support is an essential part of its
management. Early enteral nutrition (EN) is vital to maintain theience Foundation of China
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rvision of the study. QX
, GJX, and YLL acquired the
r analysis and interpreta-
he statistical analysis. The
x: þ86 28 85423373.
g).
nc. This is anopenaccessarticleumucosal integrity of the gastrointestinal (GI) tract, and helps
prevent bacterial translocation and the infection of sterile
pancreatic necrosis [1,2]. A recent meta-analysis compared the
efﬁcacy of total EN and total parenteral nutrition (TPN), and
demonstrated that, in patients with predicted severe AP, total EN
was associated with lower mortality, fewer infectious compli-
cations, decreased organ failure, and a lesser need for surgical
intervention than TPN [3]. The international consensus guide-
lines on nutrition therapy for AP make a few key proposals [4].
First, nutrition support therapy is generally not required for
patients with mild to moderate AP, and can be reserved for pa-
tients with severe AP. Second, EN is preferred to PN, with PN used
only when EN is contraindicated or not feasible. These guidelines
further highlight the importance of early nutrition support
therapy in patients with severe AP [1,4].nder theCCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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on resolution of abdominal pain and normalization of laboratory
ﬁndings, including pancreatic amylase and lipase [5]. However,
emerging data from recent studies suggest that normalization of
serum lipase level is not a necessary prerequisite for recom-
mencing oral feeding [6,7]. In an earlier prospective randomized
controlled trial (RCT), we found that early oral refeeding (EORF)
based on hunger in patients with mild AP was safe and reduced
the hospital length of stay (LOS) [8]. Patients recommenced oral
feeding when they were hungry, without the remission of
symptoms or normalization of biochemical markers. However,
the effectiveness of EORF based on hunger in patients with
moderate or severe AP remains unclear. Therefore, the aim of this
study was to determine the feasibility and safety of EORF based
on hunger in patients with moderate or severe AP by comparing
EORF with conventional oral refeeding (CORF).
Materials and methods
Study design and setting
This was a single-center, prospective, RCT. The study protocol was approved
by the institutional review board (Ethics and Human Research) of our institution.
The registration number of the trial was ChiCTR-TRC-12002994. The study was
conducted at the Department of Integrative Medicine, West China Hospital,
Sichuan University. The Department of Integrative Medicine is the research
center for pancreas disease in Sichuan province and is the national key con-
struction unit on pancreas disease in China.
All eligible adult patients admitted to the Department of Integrative Medi-
cine with AP between January 1, 2011 and December 31, 2012, were considered
for inclusion in the study, and written informed consent was obtained from all
participants. All authors had full access to all study data, and have reviewed and
approved the ﬁnal manuscript.
Inclusion and exclusion criteria
The diagnosis and severity of AP were established according to the 2012
revision of the Atlanta classiﬁcation [9]. Brieﬂy, mild AP is characterized by the
absence of organ failure and the absence of local and systemic complications.
Moderately severe AP is characterized by the presence of transient organ failure
(<48 h) and/or local or systemic complications in the absence of persistent organ
failure. Severe AP is characterized by persistent organ failure (>48 h). Organ
failures were deﬁned by the Modiﬁed Marshall Scoring System [9]. Local com-
plications were peripancreatic ﬂuid collections, pancreatic and peripancreatic
necrosis, pseudocysts, and walled-off necrosis. Systemic complications included
exacerbation of underlying heart disease, chronic diabetes, obstructive lung
disease, and chronic liver disease. The inclusion criteria were acute abdominal
pain accompanied by elevated serum amylase and/or lipase levels (3-fold above
the upper reference limit) and unequivocal evidence of AP on ultrasound and
computed tomography. The exclusion criteria were:
1. Age <18 y or >70 y;
2. Abdominal pain lasting >72 h before admission;
3. Mild AP;
4. Pregnant or breastfeeding;
5. Pancreatic neoplasm, endoscopic retrograde cholangiopancreatography, or
trauma etiology;
6. The possibility of poor oral intake or prolonged hospitalization for reasons
other than pancreatitis, such as gastroparesis or surgical intervention;
7. Admission to the intensive care unit for intubation; and
8. Surgical intervention for infected pancreatic necrosis or pancreatic
hemorrhage.
Although some patients with chronic pancreatitis had multiple ﬂare-ups
during the study period, each patient only participated once during the study
period, and the patients involved in the study had no complications during last
episode that could affect oral refeeding in the present study. An adverse event
was deﬁned as abdominal pain and distention relapse or other evidence of AP.
Study protocol
Eligible patients were consecutively enrolled and randomized to one of the
two groups. Randomization was based on a computer-generated randomization
list generated by an independent statistician who was not involved in the rest ofthe study, and took place in a consultation before the initiation of oral-feeding
preparation on the same day that patients agreed to participate in the study.
Only the investigators were blinded to the refeeding regimen. The clinician was
not blinded to the regimen because of obvious trial indexes. All patients received
conservative treatment according to their individual conditions, including
limited PN if they were in malnutrition and EN was contraindicated or not
feasible, prophylactic antibiotics if they were at risk for infection, glucose control
(insulin or acarbose oral) if they were at risk for hyperglycemia, treatment to
maintain the homeostasis, appropriate ﬂuid resuscitation therapy, and Tradi-
tional Chinese Medicine (TCM) formulation. TCM, such as Da-Cheng-Qi decoc-
tion, is widely used for the treatment of AP in China and has been used for several
decades [10,11]. The severity of AP and nutritional status were assessed on
admission and at frequent intervals thereafter. PN was given after adequate ﬂuid
resuscitation and when the patient had achieved full hemodynamic stabilization
(usually 48–72 h after admission). Adequate protein delivery (1.2–2.0 g/kg daily)
and calories (15–30 kcal/kg daily) were given to patients according to their in-
dividual condition [1,12]. The volume of PN was gradually reduced after oral
refeeding (usually 12–24 h after the ﬁrst oral intake). The decision for adminis-
tering these treatments was made by a multidisciplinary team.
Patients in the EORF group recommenced oral feeding once they felt hungry
regardless of laboratory parameters. Patients in the CORF group recommenced
oral refeeding once their abdominal pain resolved and biochemical markers had
normalized. The diet was gradually progressed from clear liquid to a low-fat solid
diet that comprised foods such as porridge and vegetables in the early stage, then
steamed bread and rice, and ﬁnally an ordinary diet. Hospital discharge was
planned on the basis of the resolution of clinical symptoms and the patient’s
tolerance of a solid diet for at least 24 h. All patients were monitored daily for
vital signs, ﬂuid intake, urinary output, food intake, and GI symptoms. Serum
lipase, amylase, albumin, and blood glucose levels and leukocyte count were
determined before and after the initiation of oral refeeding or at the time of
suspected disease recurrence. The investigators were blinded to the refeeding
regimen.
Outcome measures
The primary outcome measure was hospital LOS. The secondary outcome
measures were the duration of fasting (determined from the onset of abdominal
pain) and the subjective tolerance to food, including the relapse rate and the
degree of transitional abdominal distension and/or abdominal pain after the ﬁrst
ingestion of orally consumed food, which were evaluated by an independent
assessor who did not know the group assignment. Laboratory ﬁndings and
complications were also measured.
Statistical methods
All data entry, data management, and analyses were performed at the
Department of Integrative Medicine, West China Hospital, Sichuan University. All
outcomes were analyzed with the Package for Encyclopaedia Medical Statistics
3.1 for Windows medical statistics software, which was provided by the
Department of Health Statistics, West China School of Public Health, Sichuan
University. Continuous variables were expressed as mean  SD if they were
normally distributed, and median and interquartile range if they were non-
normally distributed. Categorical variables are expressed as frequency count.
We used t test or c2 test in our study. P < 0.05 was considered statistically
signiﬁcant.
Results
Baseline characteristics
We screened 1052 potential candidates with AP for inclusion
in the study, and 146 eligible patients with moderate or severe
AP were included in the randomization (Fig. 1). The main reason
for exclusion was mild AP (n ¼ 654, 62.2%; Fig. 1). Eight patients
dropped out after randomization (three in the EORF group and
ﬁve in the CORF group) due to refusal to follow the prescribed
oral refeeding protocol. In all, 138 patients (13%) were available
for ﬁnal analysis: 67 in the EORF group and 71 in the CORF group
(Fig. 1). The two groups were comparable in terms of sex, age,
disease etiology, disease severity, and duration of abdominal
pain before hospital admission (Table 1). White blood cell count,
hematocrit, and serum amylase on admission also were similar
in the two groups (Table 1). All patients received similar
Assessed for eligibility 
(n = 1052) 
Eligible patients
(n = 146)
Randomized
Excluded (n = 906) 
Age, < 18 y or > 70 y (n = 23)
Pregnant or breast-feeding (n = 8)
Abdominal pain lasting for >72 h before admission (n = 124)
Mild acute pancreatitis (n = 654)
Etiologies being pancreatic neoplasm, encoscopic retrograde 
cholangio-pancreatography or trauma (n = 25)
Requirement of admission to the intensive care unit or surgical 
intervention (n = 72)
Allocated to conventional oral refeeding group (n =  76  )
Did not receive early oral refeeding (n = 3) Did not receive conventional oral refeeding (n =  5  )Dropout
Allocated to early oral refeeding group (n = 70)
Analyzed (n =  67) Analyzed (n = 71   )Analysis
Allocation
Fig. 1. Participant screening, enrollment, randomization, and result.
X. L. Zhao et al. / Nutrition 31 (2015) 171–175 173treatment, including PN, antibiotics, gabexate mesylate, so-
matostatin, and TCM (Table 2).Outcome measures before and after oral refeeding
On the day of oral refeeding, mean serum amylase and lipase
levels had not normalized in the EORF group, and all biochemical
markers except serum triglyceride and cholesterol levels and
hematocrit value were signiﬁcantly higher in the EORF group
than in the CORF group (Table 3). At the ﬁnal measurement
before discharge, there was no statistically signiﬁcant difference
between the two groups in any major biochemical parameter
other than mean blood glucose level, which was higher in the
EORF group than in the CORF group (Table 4).
Total LOS was signiﬁcantly shorter in the EORF group than in
the CORF group (13.7 5.4 d versus 15.76.2 d; P¼ 0.0398), and
the duration of fasting after the onset of abdominal pain was
shorter (8.3  3.9 d versus 10.5  5.1 d; P ¼ 0.0047). However,
there was no difference in LOS after reinitiating oral feeding
between the two groups (5.4 2.4 d in the EORF group versus 5.3
 2.9 d in the CORF group; P¼ 0.7404). Therewere no differencesTable 1
Baseline patient characteristics*
EORF (n ¼ 67) CORF (n ¼ 71) P-value
Female 24 (35.8) 28 (39.4) 0.9177
Age (y) 51 (24–72) 48 (21–74)
Etiology
Biliary 13 (19.4) 16 (22.5) 0.6517
Alcoholic 12 (17.9) 14 (19.7) 0.7861
Hyperlipidemia 33 (49.3) 29 (40.9) 0.3210
Miscellaneous 9 (13.4) 12 (16.9) 0.5707
WBC count (109/L) 12.87  5.94 12.99  3.56 0.8850
Hematocrit 0.39  0.44 0.40  0.55 0.9066
Serum amylase (IU/L) 1523  584 1357  689 0.1302
Serum lipase (IU/L) 1024  315 945  358 0.1720
Ranson score 3.4  1.8 3.9  1.1 0.0966
CT severity index 4.7  1.8 5.1  1.8 0.1652
Severity
Moderate 45 (67.2) 56 (78.9) 0.1207
Severe 22 (32.8) 15 (21.1) 0.1207
First onset of acute pancreatitis 59 (88.1) 64 (90.1) 0.6946
Duration of APPTA, days 1.7  1.3 1.5  1.2 0.3490
APPTA, abdominal pain before admission; CORF, conventional oral refeeding; CT,
computed tomography; EORF, early oral refeeding; WBC, white blood cell
* Data are n (%), median (range), or mean  SD.between the two groups in terms of abdominal pain relapse,
abdominal distension, organ failure, and occurrence of local or
systemic complications before discharge from hospital (Tables 5
and 6).Discussion
Moderate and severe AP often causes complications and/or
organ failure, leading to high-catabolic, hypermetabolic, and
hyper-dynamic stress with high morbidity and mortality. Over
the past decade, nutritional support has become a key element in
the treatment of moderate and severe AP. Specialized nutrition is
indicated from admission, with EN preferred over PN [1,13].
However, there is insufﬁcient information on the optimal criteria
for oral refeeding in AP patients. The usual criteria for reinitiating
oral feeding are the absence of abdominal pain, nausea and
vomiting, and the restoration of appetite and normalization of
laboratory ﬁndings including serum amylase and lipase levels.
In the present study, we investigated an alternative approach
to reinitiating feeding that was based on hunger, without the
remission of abdominal pain or normalization of pancreatic
amylase and lipase. Our results demonstrated that EORF based
on this approach decreased the duration of both fasting and
hospitalization. These beneﬁts are clearly in accord with the
European Society for Clinical Nutrition and Metabolism guide-
lines, which state that “oral food intake should be tried as soon as
possible” [1].
Data to support EORF without normalization of serum pa-
rameters are increasingly convincing. The results of an open
randomized multicenter trial suggested that normalization ofTable 2
Therapeutic data*
EORF (n ¼ 67) CORF (n ¼ 71) P-value
Parenteral nutrition 65 (97) 69 (97.2) 0.6536
Antibiotics 66 (98.5) 71 (100) 0.9768
Gabexate mesylate 17 (25.4) 29 (40.8) 0.0540
Somatostatin analogs 16 (23.9) 26 (36.6) 0.1041
Narcotic drug 29 (43.3) 30 (42.3) 0.9027
TCM oral intake 62 (92.5) 68 (95.8) 0.6535
TCM enema 57 (85.1) 66 (93) 0.1370
EORF, early oral refeeding; CORF, conventional oral refeeding; TCM, Traditional
Chinese Medicine
* Data are n (%).
Table 3
Laboratory parameters before oral refeeding*
EORF (n ¼ 67) CORF (n ¼ 71) P-value
Serum amylase (IU/L) 512  558 304  402 0.0128y
Serum lipase (IU/L) 596  615 367  518 0.0192y
WBC count (109/L) 15.2  6.8 12.1  5.2 0.0030y
Hematocrit 0.36  0.05 0.37  0.05 0.2424
Blood glucose (mmol/L) 9.3  3.5 8.1  3.4 0.0462y
Serum triglyceride (mmol/L) 2.7  2.3 3.6  5.5 0.2036
Serum cholesterol (mmol/L) 4.0  2.1 4.2  2.5 0.5574
EORF, early oral refeeding; CORF, conventional oral refeeding; WBC, white blood
cell
* Data are mean  SD.
y Signiﬁcance of the differences between EORF and CORF.
Table 5
Clinical parameters before discharge*
EORF (n ¼ 67) CORF (n ¼ 71) P-value
Biochemical parameters
Serum amylase > ULOR 9 (13.4) 14 (19.7) 0.3221
Serum lipase > ULOR 32 (47.8) 23 (32.4) 0.0654
Blood glucose > ULOR 12 (17.9) 3 (4.2) 0.0098y
Serum triacylglycerol > ULOR 14 (21.0) 17 (24.0) 0.6681
Serum cholesterol > ULOR 0 1 0.9768
Clinical events
Abdominal pain relapse 7 (10.5) 10 (14.1) 0.5159
Abdominal distention 8 (12.0) 8 (11.3) 0.9018
APTOR (d) 8.3  3.9 10.5  5.1 0.0047y
DHAOR (d) 5.4  2.4 5.3  2.9 0.7404
LOS (d) 13.7  5.4 15.7  6.2 0.0398y
APTOR, abdominal pain to oral refeeding; CORF, conventional oral refeeding;
DHAOR, duration of hospitalization after oral refeeding; EORF, early oral
refeeding; LOS, length of stay; ULOR, upper limit of reference
* Data are n (%) or mean  SD.
y Signiﬁcance of the differences between EORF and CORF.
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patients with mild AP [6], and an RCT showed that nasogastric
tube feeding commenced within 24 h of hospital admission was
well tolerated in patients with mild to moderate AP [14].
Furthermore, it has been reported that immediate oral refeeding
is feasible and may accelerate recovery without adverse GI
events, at least in patients with mild AP [15]. Our previous study
also showed that EORF based on subjective feelings of hunger
rather than CORF guidance was a safe approach in the treatment
of patients with mild AP [8].
There is also evidence that EORF may be beneﬁcial for pa-
tients with in severe AP. A multicenter RCT showed that imme-
diate oral feeding (<24 h) in patients with mild AP was feasible
and signiﬁcantly shortened the LOS compared with traditional
fasting (4 versus 6 d; P < 0.05) [16]. In this study, we used a
moderated reinitiation protocol based on hunger in patients with
moderate and severe AP. Our results showed that this EORF
protocol based on hunger was safe and effective, and decreased
the duration of fasting and the total LOS by approximately 2 d.
This may suggest that subjective feelings of hunger reﬂected
recovery of GI dysfunction and indicated that patients were
ready for a trial of food. Clinical data strongly support the
concept that early EN can decrease complications, LOS, and
mortality in patients with AP [14,17,18]. Therefore, EORF based on
hunger may be appropriate for the management of AP, and
hunger may be a useful indicator for reinitiation of oral intake.
Compared with CORF, EORF had no major adverse effects on
most biochemical parameters, with the exception of blood
glucose levels. After the initiation of oral feeding, mean blood
glucose levels and the percentage of patients with hyperglyce-
mia were higher in the EORF group than in the CORF group,
suggesting that EORF may have been harmful to glucose control
in patients with severe AP. This ﬁnding contradicted our previous
study on patients with mild AP, where EORF was beneﬁcial for
blood glucose control [19]. Hyperglycemia is a common meta-
bolic complication of AP, particularly severe AP. One recentTable 4
Laboratory parameters before discharge*
EORF (n ¼ 67) CORF (n ¼ 71) P-value
Mean WBC count (109/L) 10.7  4.9 8.8  6.5 0.0632
Hematocrit 0.35  0.04 0.35  0.05 1.0000
Blood glucose (mmol/L) 7.8  3.4 6.3  2.2 0.0030y
Serum triglyceride (mmol/L) 3.7  2.3 3.1  3.4 0.2242
Serum cholesterol (mmol/L) 4.4  7.6 43.7  1.1 0.4623
EORF, early oral refeeding; CORF, conventional oral refeeding; WBC, white blood
cell
* Data are mean  SD.
y Signiﬁcance of the differences between EORF and CORF.systematic review showed that patients with AP often develop
prediabetes and/or diabetes mellitus after discharge from hos-
pital, and have a greater than twofold increased risk for diabetes
mellitus over 5 y [20]. Although it has been proposed that
excessive nutrition in EORF can cause excessive glucose intake
and lead to hyperglycemia, this view is somewhat rebutted by
recent systematic reviews [21,22]. For example, when compared
with both late EN and PN, early ENwas associatedwith improved
blood glucose control and a signiﬁcantly decreased incidence of
hyperglycemia in patients with AP [19,20]. Some evidence sug-
gests that in humanpancreatitis the injured pancreasmay be less
responsive to stimulation by food [23,24]. Therefore, the seri-
ously injured pancreas in severe AP may respond poorly to EORF,
more readily resulting in hyperglycemia compared with mild AP.
This may explain the different inﬂuence of EORF on blood
glucose levels in severe and mild AP. Although early resumption
of enteral feeding may result in higher glucose levels, stricter
glucose-control protocols can be used to manage this risk.
Further research is required to clarify this issue.
A major concern of EROF in AP is premature oral refeeding
with intolerance to the reintroduced diet, which can cause AP
relapse and prolonged hospital LOS. A meta-analysis and two
prospective studies reported that intolerance to refeeding
occurred in 21% to 25% of patients with AP [25–27]. Our study
showed that there were no differences between EORF and CORF
in terms of abdominal pain relapse, abdominal distension, organ
failure, and local pancreatic complications, suggesting that the
EORF based on hunger is feasible in patients with moderate
or severe AP. These ﬁndings are consistent with a previous
meta-analysis [22], which demonstrated that in comparisonwithTable 6
Complications*
EORF (n ¼ 67) CORF (n ¼ 71) P-value
Persistent organ failure 22 (32.8) 15 (21.1) 0.1207
Transient organ failure 8 (11.9) 6 (8.5) 0.4974
Pancreatic necrosis 16 (23.9) 26 (36.6) 0.1041
Pancreatic ﬂuid collection 37 (55.2) 49 (69.0) 0.0948
Pancreatic pseudocyst 11 (16.4) 10 (14.1) 0.7029
Pancreatic infectious 3 (4.5) 5 (7.0) 0.7795
Pleural effusion 20 (29.9) 27 (38.0) 0.3110
Gastrointestinal bleeding 2 (23.0) 1 (1.41) 0.9595
Pancreatic portal hypertension 3 (4.5) 2 (2.8) 0.9473
CORF, conventional oral refeeding; EORF, early oral refeeding
* Data are n (%).
X. L. Zhao et al. / Nutrition 31 (2015) 171–175 175late EN or TPN, ENwithin 48 h of admission improved the clinical
outcomes of AP by decreasing complications such as infection
and organ failure. It is possible that the recurrence of abdominal
pain during the reinitiation of an oral diet is related to ingestion
of a larger volume of food rather than the renewed release of
enzymes [28]. In a typical oral-refeeding protocol, the diet is
reintroduced gradually, starting with small amounts of clear
liquids for the ﬁrst 24 h. If tolerated, the diet is gradually changed
to a soft, low-fat regimen followed by a solid diet.
Several limitations to our work should be recognized. First,
the estimated daily energy intake may not have been accurate in
every patient because the energy in porridge and vegetables is
difﬁcult to calculate accurately. However, apart from the time at
which refeeding was initiated, the refeeding protocol and the PN
protocol were similar in both groups. Second, this study was
conducted in a single center. Although this center sees a large
volume of patients with AP (>1000 patients/y), caution should
be taken when generalizing our results.
Conclusions
In patients with moderate or severe AP, EORF based on hun-
ger was safe and superior to CORF. EORF was associated with
shorter hospital LOS and did not increase clinical complications.
We believe that EORF based on hunger should be considered as a
valid option in the management of AP. Although it may increase
the risk for hyperglycemia, this could be attenuated by a strict
glucose-control protocol. Further studies in multiple centers are
necessary to conﬁrm the reliability and generalizability of our
ﬁndings.
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